

ASX ANNOUNCEMENT

5 July 2021



CANNTAB UPDATE

Cann Global Limited (ASX:CGB) (“Company” or the “Company”) had previously advised the market on 17 June that the shipment of two of the six Canntab products was imminent. The company is pleased to advise that the unique CBD 12.5mg and CBD 25mg pharmaceutical grade hard pill formulations have been received in Australia.

Canntab’s CBD proprietary immediate release cannabidiol formulations will be available for ordering by pharmacies once the shipment has cleared customs. The products can be prescribed by practitioners via the Special Access Scheme Category B application pathway. The SAS is a mechanism by which individual patients can access an unapproved therapeutic good through their health practitioner. It allows certain health practitioners to access therapeutic goods that are not included in the Australian Register of Therapeutic Goods (ARTG) for a single patient.

Cann Global continue to work closely with Canntab and will update the market when the remaining four products ordered have been received in the country.

ABOUT CANNGLOBAL

Cann Global Limited (ASX:CGB) is a driving force in the hemp food and medical Cannabis industries. Our strength comes from our team’s core competencies and expertise, and our solid and strategic partnerships with experts in Australia, USA, Israel, Asia and Canada. We are working under the relevant legislation to ensure that the future in medical cannabis and natural foods will allow medical practitioners, patients, and consumers to gain access to the right information, as well as the safest, most effective and sustainable products. Cann Global also has a keen focus on innovation and the pursuit of medical advancement through vital research into the safe use of cannabis for patients, which has the potential to deliver significant upside for shareholders.

AUTHORITY AND CONTACT DETAILS

This announcement has been authorised for release by Sholom Feldman, Managing Director. For further information please contact Investor Relations on +61 (0)2 8379 1832, or via email at investorrelations@cannglobal.com.au

Level 21, 133 Castlereagh Street,
Sydney NSW 2000 - Australia

Telephone: (02) 8379 1832

investorrelations@cannglobal.com.au

www.cannglobal.com.au